COVID-19 vaccination and myasthenia gravis

Anat Arbel; Haya Bishara; Ofra Barnett-Griness; Shai Cohen; Ronza Najjar-Debbiny; Naomi Gronich; Eitan Auriel; Walid Saliba

doi:10.1111/ene.16087

COVID-19 vaccination and myasthenia gravis

Eur J Neurol. 2023 Dec;30(12):3989-3990. doi: 10.1111/ene.16087. Epub 2023 Oct 5.

Authors

Anat Arbel^{1

2}, Haya Bishara³, Ofra Barnett-Griness^{4

5}, Shai Cohen^{1

2}, Ronza Najjar-Debbiny^{2

6}, Naomi Gronich^{2

5}, Eitan Auriel^{7

8}, Walid Saliba^{2

5

9}

Affiliations

¹ Department of Internal Medicine B, Lady Davis Carmel Medical Center, Haifa, Israel.
² Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
³ Department of Neurology, Lady Davis Carmel Medical Center, Haifa, Israel.
⁴ Statistical Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
⁵ Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.
⁶ Infection Control and Prevention Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
⁷ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
⁸ Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.
⁹ Translational Epidemiology Unit and Research Authority, Lady Davis Carmel Medical Center, Haifa, Israel.

PMID: 37797299
DOI: 10.1111/ene.16087

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Myasthenia Gravis*
Receptors, Cholinergic
Vaccination / adverse effects

Substances

COVID-19 Vaccines
Receptors, Cholinergic